Shibali Das

Dr. Shibali Das

Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO 63110, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2019 in Nature
Verified
Journal Article
Closed access
PDF file
AAAmanda Ardain
Amanda Ardain
RDRacquel Domingo-Gonzalez
Racquel Domingo-Gonzalez
SDShibali Das
Shibali Das
SKSamuel W. Kazer
Samuel W. Kazer
NHNicole C. Howard
Nicole C. Howard
SKShabaana A. Khader
Shabaana A. Khader

1 June 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NSNinecia R. Scott
Ninecia R. Scott
RSRosemary Swanson
Rosemary Swanson
NANoor Al-Hammadi
Noor Al-Hammadi
RDRacquel Domingo-Gonzalez
Racquel Domingo-Gonzalez
RJRangel Moreno Javier
Rangel Moreno Javier
SKShabaana A. Khader
Shabaana A. Khader
Neutrophil accumulation is associated with lung pathology during active tuberculosis (ATB). However, the molecular mechanism or mechanisms by which neutrophils accumulate in the lung and contribute to TB immunopathology are not fully delineated. Using the well-established mouse model of TB, our new data provide evidence that the alarmin S100A8/A9 mediates neutrophil accumulation during progression to chronic TB. Depletion of neutrophils or S100A8/A9 deficiency resulted in improved Mycobacterium tuberculosis (Mtb) control during chronic but not acute TB. Mechanistically, we demonstrate that, following Mtb infection, S100A8/A9 expression is required for upregulation of the integrin molecule CD11b specifically on neutrophils, mediating their accumulation during chronic TB disease. These findings are further substantiated by increased expression of S100A8 and S100A9 mRNA in whole blood in human TB progressors when compared with nonprogressors and rapidly decreased S100A8/A9 protein levels in the serum upon TB treatment. Furthermore, we demonstrate that S100A8/A9 serum levels along with chemokines are useful in distinguishing between ATB and asymptomatic Mtb-infected latent individuals. Thus, our results support targeting S100A8/A9 pathways as host-directed therapy for TB.

22 December 2016 in Nature Communications
Verified
Journal Article
Open access
KGKristin L. Griffiths
Kristin L. Griffiths
MAMushtaq Ahmed
Mushtaq Ahmed
SDShibali Das
Shibali Das
RGRadha Gopal
Radha Gopal
WHWilliam Horne
William Horne
SKShabaana A. Khader
Shabaana A. Khader
The development of a tuberculosis (TB) vaccine that induces sterilizing immunity to Mycobacterium tuberculosis infection has been elusive. Absence of sterilizing immunity induced by TB vaccines may be due to delayed activation of mucosal dendritic cells (DCs), and subsequent delay in antigen presentation and activation of vaccine-induced CD4+ T-cell responses. Here we show that pulmonary delivery of activated M. tuberculosis antigen-primed DCs into vaccinated mice, at the time of M. tuberculosis exposure, can overcome the delay in accumulation of vaccine-induced CD4+ T-cell responses. In addition, activating endogenous host CD103+ DCs and the CD40–CD40L pathway can similarly induce rapid accumulation of vaccine-induced lung CD4+ T-cell responses and limit early M. tuberculosis growth. Thus, our study provides proof of concept that targeting mucosal DCs can accelerate vaccine-induced T-cell responses on M. tuberculosis infection, and provide insights to overcome bottlenecks in TB vaccine efficacy.

29 January 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MAMushtaq Ahmed
Mushtaq Ahmed
STShyamala Thirunavukkarasu
Shyamala Thirunavukkarasu
BRBruce A Rosa
Bruce A Rosa
KTKimberly A. Thomas
Kimberly A. Thomas
SDShibali Das
Shibali Das
SKShabaana A. Khader
Shabaana A. Khader
One quarter of the world’s population is infected with Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). Although most infected individuals successfully control or clear the infection, some individuals will progress to TB disease. Immune correlates identified using animal models are not always effectively translated to human TB, thus resulting in a slow pace of translational discoveries from animal models to human TB for many platforms including vaccines, therapeutics, biomarkers, and diagnostic discovery. Therefore, it is critical to improve our poor understanding of immune correlates of disease and protection that are shared across animal TB models and human TB. In this study, we have provided an in-depth identification of the conserved and diversified gene/immune pathways in TB models of nonhuman primate and diversity outbred mouse and human TB. Our results show that prominent differentially expressed genes/pathways induced during TB disease progression are conserved in genetically diverse mice, macaques, and humans. In addition, using gene-deficient inbred mouse models, we have addressed the functional role of individual genes comprising the gene signature of disease progression seen in humans with Mtb infection. We show that genes representing specific immune pathways can be protective, detrimental, or redundant in controlling Mtb infection and translate into identifying immune pathways that mediate TB immunopathology in humans. Together, our cross-species findings provide insights into modeling TB disease and the immunological basis of TB disease progression.

23 May 2017 in F1000Research
Verified
Journal Article
Open access
PDF file
SDShibali Das
Shibali Das
SKShabaana Khader
Shabaana Khader
The interleukin-17 (IL-17) family cytokines, such as IL-17A and IL-17F, play important protective roles in host immune response to a variety of infections such as bacterial, fungal, parasitic, and viral. The IL-17R signaling and downstream pathways mediate induction of proinflammatory molecules which participate in control of these pathogens. However, the production of IL-17 can also mediate pathology and inflammation associated with infections. In this review, we will discuss the yin-and-yang roles of IL-17 in host immunity to pathogens.

5 October 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
RDRacquel Domingo-Gonzalez
Racquel Domingo-Gonzalez
SDShibali Das
Shibali Das
KGKristin L. Griffiths
Kristin L. Griffiths
MAMushtaq Ahmed
Mushtaq Ahmed
MBMonika Bambouskova
Monika Bambouskova
SKShabaana A. Khader
Shabaana A. Khader
Mycobacterium tuberculosis ( Mtb ) is a global health threat, compounded by the emergence of drug-resistant strains. A hallmark of pulmonary tuberculosis (TB) is the formation of hypoxic necrotic granulomas, which upon disintegration, release infectious Mtb . Furthermore, hypoxic necrotic granulomas are associated with increased disease severity and provide a niche for drug-resistant Mtb . However, the host immune responses that promote the development of hypoxic TB granulomas are not well described. Using a necrotic Mtb mouse model, we show that loss of Mtb virulence factors, such as phenolic glycolipids, decreases the production of the proinflammatory cytokine IL-17 (also referred to as IL-17A). IL-17 production negatively regulates the development of hypoxic TB granulomas by limiting the expression of the transcription factor hypoxia-inducible factor 1α (HIF1α). In human TB patients, HIF1α mRNA expression is increased. Through genotyping and association analyses in human samples, we identified a link between the single nucleotide polymorphism rs2275913 in the IL-17 promoter (–197G/G), which is associated with decreased IL-17 production upon stimulation with Mtb cell wall. Together, our data highlight a potentially novel role for IL-17 in limiting the development of hypoxic necrotic granulomas and reducing disease severity in TB.